Ann: AusCann to Accelerate Human Drug Development Program, page-11

First 11 Last

Share
Profile

Follow
Scott th Ratbag

44,314 Posts.

642

21/09/21

17:56

Post #: 56244840
Share

Originally posted by AusCannOfficial: ↑

For clarity, the engagement is to outsource initial desktop research to evaluate opportunities to accelerate human drug development, by leveraging the data and assets that AusCann has already generated to date, in specific therapeutic areas that AusCann has pre-determined.

The team that we have within AusCann are highly capable, having designed, managed and executed significant cannabinoid-based research to date, including multiple in-vitro/in-vivo toxicological studies, randomised placebo-controlled clinical trials, pharmacokinetic studies and various other research activities in both human and animal across Canada, Europe, U.S and Australia.

This work has led to the submission of the first Investigational New Animal Drug file with the FDA-CVM for our cannabinoid-based veterinary drug program in the U.S, and the submission of the first cannabinoid-based regulatory dossier with the APVMA for an Australian veterinary medicine containing cannabidiol.

Outsourcing the initial gap analysis to a highly specialised Clinical Research Organisation enables AusCann to quickly gather a broad cross-section of scientific and regulatory input from industry experts, while allowing the AusCann team to remain focused on our upcoming milestones, which are our priority.

Expand

thank you for your post ACO.....

but what has happened to Neuvis? we've had no news on this for over 6 months and Neuvis was supposed to be our entry into prescription-only medicinal cannabis.

AC8 Price at posting: 8.7¢ Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

AX8

Accelerate finds 1.28% lithium at Prinsep in WA, including 150m 'halo' zone

VMM

Virdis Mining flags breakthrough with 76% neodymium and praseodymium recoveries

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

There are more pages in this discussion • 19 more messages in this thread...

First 11 Last

Add AC8 (ASX) to my watchlist

(20min delay)
Last 4.0¢		Change 0.000(0.00%)		Mkt cap ! $17.62M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Ann: AusCann to Accelerate Human Drug Development Program, page-11

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Accelerate finds 1.28% lithium at Prinsep in WA, including 150m 'halo' zone

Virdis Mining flags breakthrough with 76% neodymium and praseodymium recoveries

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Featured News

Featured News

Ann: AusCann to Accelerate Human Drug Development Program, page-11

Top Stories

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Accelerate finds 1.28% lithium at Prinsep in WA, including 150m 'halo' zone

Virdis Mining flags breakthrough with 76% neodymium and praseodymium recoveries

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Featured News

Featured News